Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

84 public trials 18 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

NCT01087294

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Hodgkin Disease, +15 more
Locations
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • National Marrow Donor Program Minneapolis, Minnesota, United States
View Trial Details
Completed

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

NCT04849416

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +19 more
Locations
  • Wannan Medical College Yijishan Hospital Wuhu, Anhui, China
  • Beijing Cancer hospital Beijing, Beijing Municipality, China
  • Southern Medical University Nanfang Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 22 locations
View Trial Details
Completed

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

NCT03598608

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +9 more
Locations
  • Banner MD Anderson Cancer Center ( Site 0020) Gilbert, Arizona, United States
  • City of Hope ( Site 0001) Duarte, California, United States
  • Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007) Los Angeles, California, United States
  • Pacific Cancer Care ( Site 0006) Monterey, California, United States
View all 25 locations
View Trial Details
Completed

A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)

NCT04317066

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Nagoya University Hospital ( Site 0002) Nagoya, Aichi-ken, Japan
  • Hokkaido University Hospital ( Site 0006) Sapporo, Hokkaido, Japan
  • Kindai University Hospital ( Site 0001) Sayama, Osaka, Japan
  • National Hospital Organization Disaster Medical Center ( Site 0007) Tachikawa, Tokyo, Japan
View Trial Details

Related conditions